Simvastatin monotherapy as a potential option for statin‐associated muscle symptoms: a case report. (18th July 2016)

• Record Type: Journal Article
• Authors: Qu, H.; Guo, M.; Kou, N.; Wu, H.‐t.; Zhang, Y.; Gao, Z.‐y.; Shi, D.‐z.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 41:Number 5(2016:Oct.)
• Page Start: 568
• Page End: 571
• Publication Date: 2016-07-18
• Subjects: alternative statin -- simvastatin -- statin‐associated muscle symptoms; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.12419
• Languages: English
• ISSNs: 0269-4727

Abstract

Summary: What is known and objectives: Choosing an alternative statin is recommended when managing statin‐associated muscle symptoms (SAMS) and new hydrophilic statins are often suggested. We report on a case of statin‐associated muscle damage that was successfully managed by simplifying the patient's combination therapy with simvastatin–ezetimibe to simvastatin alone. Case summary: The patient experienced SAMS when he was successively treated with atorvastatin, rosuvastatin, Xuezhikang capsule and combined simvastatin/ezetimibe therapy. However, the patient tolerated simvastatin therapy well even at a dose of 40 mg/day. What is new and conclusion: Our case suggests that patients with SAMS who are intolerant to a wide variety of statins may be successfully managed with simvastatin monotherapy. Abstract : In this case, the patient with statin‐associated muscle symptoms (SAMS) tolerated simvastatin therapy well, even though he could not tolerate atorvastatin, rosuvastatin, Xuezhikang capsule and combined simvastatin/ezetimibe therapy. Thus, we think that simvastatin, a lipophilic statin, may be a good choice for the patient with SAMS who is intolerant to a wide variety of other statins.